ERES East Resources Acquisition Company

Top 10 Global Pharmaceutical Company Awards $1.3 Million in Studies to eResearchTechnology for Cardiac Safety Monitoring and Information Distribution Services Phase III Program Award Demonstrates Industry Compliance With Later Phase Development Aspects of Recently Ratified ICH, E14 Guidance PHILADELPHIA, July 6 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), (NASDAQ:ERES), a leading provider of centralized electrocardiographic (ECG) collection and interpretation services, announced today that it has been awarded more than $1.3 million in cardiac safety monitoring and services from a top 10 global pharmaceutical organization for one of its key drug candidates in late phase clinical trials. The award for the Phase III program and a related Phase II trial is comprised of a number of studies with an investigator network that spans five continents. eRT will provide comprehensive support, including provision of 340 units of digital 12-lead ECG equipment designed to facilitate collection of cardiac safety data that is subsequently provided to eRT for analysis. eRT will perform digital collection, measurement, interpretation, review, and distribution of cardiac safety data through its EXPeRT(R) workflow enabled data handling technology, the first solution in production that was designed explicitly to meet emerging international regulatory guidance and technical standards. "This award illustrates industry response to the recently ratified ICH, E14 guidance, which specifies cardiac safety monitoring on all compounds in a manner consistent with therapeutic area standards, regardless of Thorough QT Study results," said Scott Grisanti, senior vice president of business development and chief marketing officer at eRT. "In addition, the agreement recognizes the value drug developers are placing on the ability to make program level awards to eRT, which offers the Project Assurance delivery methodology and global logistics and site support capabilities required to ensure success of this critical and complex initiative." Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development. Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. The sponsor may cancel this agreement at its sole discretion. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the company's financial results can be found in the company's Reports on Forms 10-K and 10-Q filed with the Securities and Exchange Commission. DATASOURCE: eResearchTechnology, Inc. CONTACT: Joan Sterlacci of eResearchTechnology, +1-908-203-6473, or Matt Hayden of Hayden Communications, +1-858-704-5065, for eResearchTechnology Web site: http://www.ert.com/

Copyright